Prognostic Role of BRAF Mutation in Stage II/III Colorectal Cancer Receiving Curative Resection and Adjuvant Chemotherapy: A Meta-Analysis Based on Randomized Clinical Trials.

Abstract excerpt

BACKGROUND AND OBJECTIVE: Studies examining the prognostic value of the BRAF mutation on relapse-free survival (RFS), disease-free survival (DFS) and overall survival (OS) in stage II/III colorectal cancer (CRC) patients receiving curative resection and adjuvant chemotherapy so far showed discrepant results. Therefore, a meta-analysis of relevant studies was performed for clarification. METHODS: Randomized trials...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Chemotherapy, Adjuvant
• Share to Colorectal Neoplasms